Seven Fleet Capital Management LP Buys New Position in Avalo Therapeutics, Inc. $AVTX

Seven Fleet Capital Management LP purchased a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 63,343 shares of the company’s stock, valued at approximately $1,150,000. Avalo Therapeutics makes up approximately 0.9% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 20th biggest position. Seven Fleet Capital Management LP owned about 0.34% of Avalo Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AVTX. Geode Capital Management LLC lifted its holdings in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after purchasing an additional 400,898 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics in the 2nd quarter worth approximately $56,000. Finally, Aberdeen Group plc acquired a new stake in Avalo Therapeutics during the third quarter valued at approximately $925,000. 87.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on AVTX shares. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Wedbush dropped their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday. Citigroup reissued an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.

Avalo Therapeutics Stock Down 4.5%

AVTX stock opened at $14.70 on Friday. The company has a market capitalization of $772.78 million, a price-to-earnings ratio of -2.69 and a beta of 0.83. Avalo Therapeutics, Inc. has a 12 month low of $4.50 and a 12 month high of $24.27. The firm has a 50 day moving average of $15.51 and a two-hundred day moving average of $16.09.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, research analysts expect that Avalo Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.

Insider Activity at Avalo Therapeutics

In other news, CFO Christopher Ryan Sullivan sold 8,458 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the sale, the chief financial officer directly owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This represents a 48.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider directly owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 112,586 shares of company stock valued at $2,089,651. Corporate insiders own 4.46% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.